Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2015

01-08-2015 | Endocrine Imaging

Pituitary stalk interruption and olfactory bulbs aplasia/hypoplasia in a man with Kallmann syndrome and reversible gonadotrope and somatotrope deficiencies

Authors: Julie Sarfati, Alexandru Saveanu, Jacques Young

Published in: Endocrine | Issue 3/2015

Login to get access

Excerpt

Kallmann syndrome (KS) is characterized by congenital hypogonadotropic hypogonadism (CHH) and anosmia/hyposmia related to aplasia/hypoplasia of the olfactory bulbs (OB) [1]. In KS, the gonadotropin deficiency is isolated, the statural growth is preserved and other pituitary functions, particularly growth hormone (GH) secretion are normal, as well as hypothalamo-pituitary morphology [2]. …
Literature
1.
L. Maione, S. Benadjaoud, C. Eloit et al., Computed tomography of the anterior skull base in Kallmann syndrome reveals specific ethmoid bone abnormalities associated with olfactory bulb defects. J. Clin. Endocrinol. Metab. 98, E537–E546 (2013)PubMedCrossRef
2.
J. Young, Approach to the male patient with congenital hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 97, 707–718 (2012)PubMedCrossRef
3.
T. Raivio, M. Avbelj, M.J. McCabe et al., Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. J. Clin. Endocrinol. Metab. 97, E694–E699 (2012)PubMedCentralPubMedCrossRef
4.
R. Reynaud, F. Albarel, A. Saveanu et al., Pituitary stalk interruption syndrome in 83 patients: novel HESX1 mutation and severe hormonal prognosis in malformative forms. Eur. J. Endocrinol. 164, 457–465 (2011)
Metadata
Title
Pituitary stalk interruption and olfactory bulbs aplasia/hypoplasia in a man with Kallmann syndrome and reversible gonadotrope and somatotrope deficiencies
Authors
Julie Sarfati
Alexandru Saveanu
Jacques Young
Publication date
01-08-2015
Publisher
Springer US
Published in
Endocrine / Issue 3/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0475-8

Other articles of this Issue 3/2015

Endocrine 3/2015 Go to the issue

Original Article

High-fat diet combined with low-dose streptozotocin injections induces metabolic syndrome in Macaca mulatta

Editorial

Improving the approach to non-diagnostic aspirates: learning from each other

Editorial

High salt intake: detrimental not only for blood pressure, but also for bone health?

Viewpoint

Does microbiota composition affect thyroid homeostasis?

Research Letter

Reduced plasma level of diazepam-binding inhibitor (DBI) in patients with morbid obesity

Letter to the Editor

Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits